Xilio Therapeutics, Inc.
XLO
$0.6998
-$0.0182-2.54%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 175.90% | 69.95% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 175.90% | 69.95% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -347.30% | 69.95% | |||
| SG&A Expenses | -16.38% | 30.66% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 33.78% | 9.30% | |||
| Operating Income | -3.72% | -1.63% | |||
| Income Before Tax | -19.44% | -1.31% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -19.44% | -1.31% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -19.44% | -1.31% | |||
| EBIT | -3.72% | -1.63% | |||
| EBITDA | -4.73% | -0.75% | |||
| EPS Basic | -72.13% | 12.25% | |||
| Normalized Basic EPS | -72.16% | 12.25% | |||
| EPS Diluted | -72.13% | 12.25% | |||
| Normalized Diluted EPS | -72.16% | 12.25% | |||
| Average Basic Shares Outstanding | -30.62% | 15.50% | |||
| Average Diluted Shares Outstanding | -30.62% | 15.50% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||